|1.||Turpie, Alexander G G: 18 articles (03/2009 - 01/2002)|
|2.||Mehta, Shamir R: 17 articles (04/2015 - 03/2005)|
|3.||Yusuf, Salim: 17 articles (05/2014 - 03/2005)|
|4.||Bauer, Kenneth A: 17 articles (09/2008 - 01/2002)|
|5.||Afzal, Rizwan: 15 articles (05/2014 - 03/2005)|
|6.||Bassand, Jean-Pierre: 15 articles (02/2010 - 03/2005)|
|7.||Chrolavicius, Susan: 14 articles (12/2010 - 12/2005)|
|8.||Eriksson, Bengt I: 13 articles (06/2013 - 01/2002)|
|9.||Granger, Christopher B: 12 articles (12/2010 - 03/2005)|
|10.||Akl, Elie A: 11 articles (01/2014 - 01/2008)|
01/01/2004 - "The further randomized, double-blind PENTHIFRA-PLUS trial showed that extending fondaparinux prophylaxis from one to four weeks after hip fracture surgery was well tolerated and, compared to one-week fondaparinux, dramatically reduced delayed venous thromboembolism events from 35.0% to 1.4% (p<0.001). "
01/01/2008 - "In a well designed trial (ARTEMIS) in acute medical patients aged > or = 60 years, fondaparinux was significantly more effective than placebo in terms of reducing the incidence of venous thromboembolism (VTE) up to day 15. "
07/01/2004 - "In patients undergoing elective hip replacement surgery, fondaparinux significantly reduced the frequency of venous thromboembolism (VTE). "
11/01/2012 - "Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study."
12/01/2007 - "The safety and efficacy of extended fondaparinux therapy for the prevention of venous thromboembolism were also evaluated. "
01/01/2013 - "In one large, placebo-controlled RCT of about 3000 patients, subcutaneous fondaparinux was associated with a significant reduction in symptomatic VTE (RR 0.15; 95% CI 0.04 to 0.50), ST extension (RR 0.08; 95% CI 0.03 to 0.22), and ST recurrence (RR 0.21; 95% CI 0.08 to 0.54) with comparable rates of major bleeding (RR 0.99; 95% CI 0.06 to 15.86) relative to placebo. "
01/01/2012 - "In a placebo-controlled RCT of about 3000 patients, fondaparinux was associated with a significant reduction in symptomatic VTE (RR 0.15; 95% CI 0.04 to 0.50), extension (RR 0.08; 95% CI 0.03 to 0.22), and recurrence of ST (RR 0.21; 95% CI 0.08 to 0.54) with comparable rates of major bleeding (RR 0.99; 95% CI 0.06 to 15.86) relative to placebo. "
12/01/2003 - "In a subgroup analysis of several large randomized trials, fondaparinux, 2.5 mg, begun < 6 h postoperatively was associated with increased major bleeding, without improved efficacy. "
05/01/2011 - "Even in the context of low access site complication rate provided by TRA, fondaparinux was effective in reducing major bleeding."
09/01/2004 - "This superior efficacy led to an overall increase in major bleeding, which was however primarily due to more fondaparinux-treated patients with bleeding indexes of 2 or greater. "
|3.||Acute Coronary Syndrome
04/01/2010 - "Fondaparinux sodium injection has been accepted for priority review by the United States Food and Drug Administration based on positive results from two pivotal, Phase III trials (OASIS 5 and 6) that evaluated its role in the treatment of a broad spectrum of patients with acute coronary syndromes (ACS). "
11/01/2005 - "Finally, a number of Phase II trials investigated the safety and efficacy of fondaparinux in patients with acute coronary syndromes, and a large Phase III program is ongoing in this setting. "
01/01/2006 - "Fondaparinux in acute coronary syndromes: improved efficacy and safety."
09/22/2010 - "Double-blind randomized parallel-group trial in 179 hospitals in 18 countries involving 2026 patients undergoing PCI within 72 hours, nested within a cohort of 3235 high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux enrolled from February 2009 to March 2010. "
01/01/2010 - "Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies."
09/23/2010 - "Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects. "
01/01/2014 - "Given the development of new thromboses in 3 of 8 patients, concern exists about the efficacy of fondaparinux in this patient population. "
03/01/2012 - "In vitro studies support the effectiveness of fondaparinux in preventing thrombus formation on mechanical heart valves. "
04/01/2011 - "Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study."
06/01/2009 - "During the 25-month study period, 219 patients were prescribed fondaparinux: 157 (71.7%) for prophylaxis and 62 (28.3%) patients for the treatment of thrombosis. "
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
07/01/2005 - "In conclusion, due to its superior efficacy and satisfactory safety, fondaparinux may substantially improve the prevention and treatment of venous thrombosis."
01/01/2002 - "This superior efficacy of fondaparinux was also demonstrated for proximal deep vein thrombosis with a reduction of 57.4%. "
11/12/2002 - "The novel anticoagulant fondaparinux proved to be effective and safe in the postoperative prevention of venous thrombosis. "
01/01/2004 - "Fondaparinux recipients had a lower incidence of proximal deep vein thrombosis (DVT) in two studies. "
01/01/2016 - "Between March 2010 and January 2013, 78 patients free from preoperative deep vein thrombosis (DVT) were enrolled, of whom 37 were randomly assigned to placebo and 41 to treatment with fondaparinux. "
|2.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|4.||Factor Xa (Coagulation Factor Xa)
|7.||Aspirin (Acetylsalicylic Acid)
|4.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)